# US 2022/0023422 A1 · Pharmaceutical composition comprising anti-human tslp receptor antibody

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0023422 A1
- Document ID: US20220023422A1
- Status: Published application
- Kind: A1
- Application number: 17/172,490
- Filed: 2021-02-10
- Published: 2022-01-27
- Earliest claimed: 2015-12-18
- Assignees: Astellas Pharma Inc.
- Applicants: Astellas Pharma Inc.
- Inventors: Megumi IKEDA; Akinori CHIKUSHI
- Web page: https://patentgrep.com/patent/US20220023422A1

## CPC

- A61K 39/39591: {Stabilisation, fragmentation}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/24: against cytokines, lymphokines or interferons
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- C07K 2317/21: from primates, e.g. man
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided is a stable pharmaceutical composition, comprising an anti-human TSLP receptor antibody, capable of inhibiting the generation of chemically modified substances, such as deamidated forms and oxidized forms, or degradants or multimers. The pharmaceutical composition comprises an anti-human TSLP receptor antibody, a pharmaceutically acceptable buffer, arginine or a pharmaceutically acceptable salt thereof, and a surfactant.

## Claims

### Claim at position 1

1: A stable pharmaceutical composition comprising an anti-human TSLP receptor antibody, a pharmaceutically acceptable buffer, arginine or a pharmaceutically acceptable salt thereof, and a surfactant, wherein the following (1) and/or (2) is contained as the anti-human TSLP receptor antibody:
(1) an anti-human TSLP receptor antibody comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 1, and a light chain consisting of the amino acid sequence of SEQ ID NO: 3, and
(2) an anti-human TSLP receptor antibody consisting of amino acid sequences of an antibody generated by a post-translational modification of the anti-human TSLP receptor antibody of (1).

### Claim at position 2 (depends on 1)

2: The pharmaceutical composition according to claim 1, wherein the pharmaceutically acceptable buffer is one, or two or more selected from the group consisting of phosphoric acid, citric acid, acetic acid, succinic acid, histidine, ascorbic acid, glutamic acid, lactic acid, maleic acid, trometamol, and gluconic acid.

### Claim at position 3 (depends on 1)

3: The pharmaceutical composition according to claim 1, wherein the pharmaceutically acceptable buffer is phosphoric acid.

### Claim at position 4 (depends on 1)

4: The pharmaceutical composition according to claim 1, wherein the concentration of the pharmaceutically acceptable buffer is 5 to 100 mmol/L.

### Claim at position 5 (depends on 1)

5: The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is a liquid preparation, or a lyophilized preparation or a spray-dried preparation.

### Claim at position 6 (depends on 5)

6: The pharmaceutical composition according to claim 5, wherein the pharmaceutical composition is a liquid preparation.

### Claim at position 7 (depends on 5)

7: The pharmaceutical composition according to claim 5, wherein when the pharmaceutical composition is a liquid preparation, a pH of the liquid preparation is 5 to 6, or when the pharmaceutical composition is a lyophilized preparation or a spray-dried preparation, a pH of a solution after reconstituting the preparation in water is 5 to 6.

### Claim at position 8 (depends on 7)

8: The pharmaceutical composition according to claim 7, wherein the pharmaceutical composition is a liquid preparation, and the pH of the liquid preparation is 5 to 6.

### Claim at position 9 (depends on 1)

9: The pharmaceutical composition according to claim 1, wherein the concentration of the arginine or a pharmaceutically acceptable salt thereof is 700 mmol/L or less.

### Claim at position 10 (depends on 1)

10: The pharmaceutical composition according to claim 1, wherein the surfactant is one, or two or more selected from the group consisting of polysorbates and poloxamer 188.

### Claim at position 11 (depends on 1)

11: The pharmaceutical composition according to claim 1, wherein the surfactant is polysorbate 80.

### Claim at position 12 (depends on 1)

12: The pharmaceutical composition according to claim 1, wherein a content of the surfactant is 0.001 to 1% (w/v).

### Claim at position 13 (depends on 1)

13: The pharmaceutical composition according to claim 1, Wherein the content of the surfactant is 0.01 to 0.2% (w/v).

### Claim at position 14 (depends on 5)

14: The pharmaceutical composition according to claim 5, wherein when the pharmaceutical composition is a liquid preparation, a content of the anti-human TSLP receptor antibody is 0.007 to 2 mmol/L, or when the pharmaceutical composition is a lyophilized preparation or a spray-dried preparation, a content of a solution after reconstituting the preparation in water is 0.007 to 2 mmol/L.

### Claim at position 15 (depends on 1)

15: The pharmaceutical composition according to claim 1, wherein when the pharmaceutical composition is stored, each content of a degradant and a multimer is 10% or less, or a content of a chemically modified substance is 50% or less.

### Claim at position 16 (depends on 1)

16: The pharmaceutical composition according to claim 1, comprising an anti-human TSLP receptor antibody comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 1, and a light chain consisting of the amino acid sequence of SEQ ID NO: 3.

### Claim at position 17 (depends on 1)

17: The pharmaceutical composition according to claim 1, comprising an anti-human TSLP receptor antibody consisting of amino acid sequences of an antibody generated by a post-translational modification of an anti-human TSLP receptor antibody comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 1, and a light chain consisting of the amino acid sequence of SEQ ID NO: 3.

### Claim at position 18 (depends on 1)

18: The pharmaceutical composition according to claim 1, comprising an anti-human TSLP receptor antibody comprising a heavy chain consisting of the amino acid sequence of amino acids 1-447 of SEQ ID NO: 1, and a light chain consisting of the amino acid sequence of SEQ ID NO: 3.

### Claim at position 19 (depends on 1)

19: The pharmaceutical composition according to claim 1, comprising an anti-human TSLP receptor antibody comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 1, and a light chain consisting of the amino acid sequence of SEQ ID NO: 3, and an anti-human TSLP receptor antibody comprising a heavy chain consisting of the amino acid sequence of amino acids 1-447 of SEQ ID NO: 1, and a light chain consisting of the amino acid sequence of SEQ ID NO: 3.
